ArticleBMC cancer2026
Efficacy and safety of low-intensity chemotherapy combined with immunotherapy in elderly patients with locally advanced and metastatic non-small cell lung cancer: a retrospective analysis.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
For advanced non-small cell lung cancer (NSCLC) lacking driver mutations, immunotherapy combined with chemotherapy is a standard treatment; however, elderly patients frequently exhibit poor tolerance to standard chemotherapy and derive limited benefit from immunotherapy alone. Thus, this retrospective study assessed the efficacy and safety of low-intensity chemotherapy combined with immunotherapy in elderly (≥ 65) patients with locally advanced and metastatic NSCLC. We included 554 patients from the PLA General Hospital who were divided into three cohorts: immune monotherapy (monotherapy group, n = 125), a combination of immunotherapy and standard chemotherapy (standard group, n = 205), and immunotherapy paired with low-intensity chemotherapy (low-intensity group, n = 224). The primary endpoints were overall survival (OS) and progression-free survival (PFS), and the secondary endpoints included the objective response rate (ORR), disease control rate (DCR), and adverse events (AEs). Compared with the monotherapy group, the low-intensity group demonstrated significantly improved median PFS (11.50 vs. 7.87 months, P < 0.001) and OS (32.20 vs. 14.97 months, P < 0.001). The inverse probability of treatment weighting (IPTW) adjustment sustained these benefits. Compared with the standard group, the low-intensity group had similar PFS and OS rates, and better safety profiles. This study indicates that low-intensity chemoimmunotherapy is superior to immune monotherapy and offers a safer alternative to standard chemoimmunotherapy in elderly NSCLC patients, suggesting its potential as a first-line treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.